In this solid tumor model, we observed complete control of outgrowth independent of GLUT1OE (Fig. 10G), however, blood analysis on days 18 and 34 post-tumor engraftment showed higher levels of circulating human T cells, and TSCM populations in mice treated with GPC2-28ζ-GLUT1 as compared to mice administered control CAR-T cells (Fig. 10H). The gene discussed is GPC2; the disease is neoplasm.